Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Swahn, M-L.
Right arrow Articles by Wei-fang, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swahn, M-L.
Right arrow Articles by Wei-fang, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 14, No. 2, 485-488, February 1999
© 1999 European Society of Human Reproduction and Embryology

Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol

M-L. Swahn1,6, M. Bygdeman2, Chen Jun-kang3, K. Gemzell-Danielsson2, Song Si3, Yang Qiu-ying3, Yang Pei-juan3, Qian Mei-ling4 and Chang Wei-fang5

1 Department of Obstetrics and Gynecology, Huddinge University Hospital, S-141 86 Huddinge, 2 Department of Woman and Child Health, Division for Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden, 3 Shanghai Institute of Planned Parenthood Research, Shanghai, 4 Shanghai Lu Wan District MCH Hospital and 5 Shanghai No. 2 Textile Hospital, China

In this two centre study, the efficacy of 200 mg mifepristone orally followed 48 h later by 0.4 mg misoprostol orally for menstrual regulation was investigated. The dose of mifepristone was taken the day before the expected day of menstruation. Each volunteer was planned to participate for up to 6 months. A plasma ß human chorionic gonadotrophin (HCG) was measured on the day of mifepristone intake. The study was disrupted prematurely due to low efficacy. In 125 treatment cycles the overall pregnancy rate was 17.6% (22 pregnancies) and the rate of continuing pregnancies (failure) was 4.0%. Eight women discontinued the study due to bleeding irregularities which were seen in 15 cycles (12%). These effects on bleeding pattern made the timing of treatment day difficult. Late luteal phase treatment with a combination of mifepristone and misoprostol is not adequately effective for menstrual regulation.

Key words: luteal phase treatment/menstrual regulation/mifepristone/misoprostol

6 To whom correspondence should be addressed


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
N. Chabbert-Buffet, G. Meduri, P. Bouchard, and I. M. Spitz
Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications
Hum. Reprod. Update, May 1, 2005; 11(3): 293 - 307.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
K. Gemzell-Danielsson and L. Marions
Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception
Hum. Reprod. Update, July 1, 2004; 10(4): 341 - 348.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
D. T Baird and A. F Glasier
Science, medicine, and the future: Contraception
BMJ, October 9, 1999; 319(7215): 969 - 972.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.